MedPath

Gebro Pharma GmbH

Gebro Pharma GmbH logo
🇦🇹Austria
Ownership
Private
Established
1947-01-01
Employees
251
Market Cap
-
Website
http://www.gebro.com

Clinical Trials

5

Active:3
Completed:2

Trial Phases

2 Phases

Phase 1:1
Phase 4:1

Drug Approvals

1

CIMA_AEMPS:1

Drug Approvals

VOLTADOL 11,6 MG/G GEL

Approval Date
Jul 14, 2025
CIMA_AEMPS

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (50.0%)
Phase 4
1 (50.0%)

Dexibuprofen 400 mg Sachet Versus Ibuprofen 400 mg Sachet in Patients With Osteoarthritis of the Hip or Knee

Phase 4
Completed
Conditions
Osteoarthritis of the Hip or Knee
Interventions
First Posted Date
2010-02-10
Last Posted Date
2012-07-10
Lead Sponsor
Gebro Pharma GmbH
Target Recruit Count
482
Registration Number
NCT01066676
Locations
🇦🇹

Rehabzentrum für Erkrankungen des rheumat. Formenkreises, Bad Hofgastein, Salzburg, Austria

🇦🇹

Rheuma Zentrum Favoriten, Vienna, Austria

S(+)-Ibuprofen Effects on Asprin Treated Volunteers

Phase 1
Completed
Conditions
Drug Interactions
First Posted Date
2007-03-02
Last Posted Date
2012-03-13
Lead Sponsor
Gebro Pharma GmbH
Target Recruit Count
72
Registration Number
NCT00442585
Locations
🇦🇹

Department of Clinical Pharmacology, Medical University Vienna, Vienna, Austria

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.